VICURON PHARMACEUTICALS INC. AND OSCIENT PHARMACEUTICALS CORPORATION ASSIGNMENT AND TERMINATION AGREEMENTAssignment and Termination Agreement • May 10th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • New York
THIS ASSIGNMENT AND TERMINATION AGREEMENT (the “Agreement”) is made effective as of the 3RD day of February, 2006 (the “Effective Date”) by and between Oscient Pharmaceuticals Corporation (formerly known as Genome Therapeutics Corporation), a Massachusetts corporation having its principal place of business at 1000 Winter Street, Suite 2200, Waltham, MA 02451, USA (“Oscient”) and Vicuron Pharmaceuticals Inc., a Delaware corporation with its principal place of business at 455 South Gulph Road, Suite 305, King of Prussia, PA 19406, USA (for itself and as successor-in-interest to Biosearch Italia, “Vicuron”). Oscient and Vicuron are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SUBLICENSING AND DISTRIBUTION AGREEMENT Dated as of February 6, 2006 MADE BETWEEN OSCIENT PHARMACEUTICALS CORPORATION AND PFIZER, S.A. DE C.V.Sublicensing and Distribution Agreement • May 10th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • New York
SUBLICENSING AND DISTRIBUTION AGREEMENT (the “Agreement”) entered into by Oscient Pharmaceuticals Corporation (“Oscient”), represented by Steven M. Rauscher, its President and Chief Executive Officer, a corporation constituted and existing under the laws of the Commonwealth of Massachusetts, United States of America, as party of the first part, Pfizer, S.A. de C.V. (“Pfizer Mexico”) (both Oscient and Pfizer Mexico may individually be referred to as a “Party” and collectively as the “Parties”), represented by Jorge Bracero Cotty, its legal representative, a corporation constituted and existing under the laws of Mexico, in accordance with the following recitals and terms:
AMENDMENT No. 5 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • May 10th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT No. 5 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 5”) is made and entered into this February 3, 2006 (the “Amendment No. 5 Effective Date”) by and between Oscient Pharmaceuticals Corporation (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, MA 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
